TAK 029 | CAS#176655-58-6 | Local Glycoprotein IIb/IIIa Receptor Inhibitor

MedKoo Cat#: 526404 | Name: TAK 029

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TAK 029 is a local glycoprotein IIb/IIIa receptor inhibitor.

Chemical Structure

TAK 029

CAS#176655-58-6

Theoretical Analysis

MedKoo Cat#: 526404

Name: TAK 029

CAS#: 176655-58-6

Chemical Formula: C18H21N5O7

Exact Mass: 419.1441

Molecular Weight: 419.39

Elemental Analysis: C, 51.55; H, 5.05; N, 16.70; O, 26.70

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

TAK 029, TAK029, TAK-029

IUPAC/Chemical Name

4-(4-Amidinobenzoylglycyl)-3-methoxycarbonyl-2-oxopiperazine-1-acetic acid

InChi Key

CBGVKPBTAJZSMX-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H21N5O7/c1-30-18(29)14-17(28)22(9-13(25)26)6-7-23(14)12(24)8-21-16(27)11-4-2-10(3-5-11)15(19)20/h2-5,14H,6-9H2,1H3,(H3,19,20)(H,21,27)(H,25,26)

SMILES Code

O=C(O)CN1C(C(C(OC)=O)N(C(CNC(C2=CC=C(C(N)=N)C=C2)=O)=O)CC1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 419.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Linneweber J, Dohmen PM, Kertzscher U, Affeld K, Konertz W. Local glycoprotein IIb/IIIa receptor inhibitor delivery from the pump surface attenuates platelet adhesion in continuous flow ventricular assist devices. Artif Organs. 2008 Oct;32(10):792-9. doi: 10.1111/j.1525-1594.2008.00632.x. PubMed PMID: 18959668. 2: Yamamoto J, Yamashita T, Ikarugi H, Taka T, Hashimoto M, Ishii H, Watanabe S, Kovacs IB. Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis. Blood Coagul Fibrinolysis. 2003 Jan;14(1):31-9. PubMed PMID: 12544726. 3: Tomita Y, Tanahashi N, Tomita M, Itoh Y, Yokoyama M, Takeda H, Schiszler I, Fukuuchi Y. Role of platelet glycoprotein IIb/IIIa in ADP-activated platelet adhesion to aortic endothelial cells in vitro: observation with video-enhanced contrast microscopy. Clin Hemorheol Microcirc. 2001;24(1):1-9. PubMed PMID: 11345228. 4: Kitamura S, Fukushi H, Miyawaki T, Kawamura M, Terashita Z, Sugihara H, Naka T. Novel non-peptide GPIIb/IIIa antagonists: synthesis and biological activities of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2 -oxopiperazinyl] acetic acids. Chem Pharm Bull (Tokyo). 2001 Mar;49(3):258-67. PubMed PMID: 11253914. 5: Tanahashi N, Fukuuchi Y, Tomita M, Tomita Y, Inoue K, Satoh H, Abe T. Adhesion of adenosine diphosphate-activated platelets to human brain microvascular endothelial cells under flow in vitro is mediated via GPIIb/IIIa. Neurosci Lett. 2001 Mar 23;301(1):33-6. PubMed PMID: 11239710. 6: Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999 Feb 9;99(5):620-5. PubMed PMID: 9950658. 7: Kawahito K, Fujimura A, Kobayashi E, Misawa Y, Fuse K. Platelet protective effect of TAK-029, a novel glycoprotein IIb/IIIa antagonist: an in vitro study. Artif Organs. 1998 Apr;22(4):348-52. PubMed PMID: 9555968. 8: Takada S, Ogawa Y. [Design and development of controlled release of drugs from injectable microcapsules]. Nihon Rinsho. 1998 Mar;56(3):675-9. Review. Japanese. PubMed PMID: 9549355. 9: Sugihara H, Fukushi H, Miyawaki T, Imai Y, Terashita Z, Kawamura M, Fujisawa Y, Kita S. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide. J Med Chem. 1998 Feb 12;41(4):489-502. PubMed PMID: 9484499. 10: Takada S, Kurokawa T, Miyazaki K, Iwasa S, Ogawa Y. Utilization of an amorphous form of a water-soluble GPIIb/IIIa antagonist for controlled release from biodegradable microspheres. Pharm Res. 1997 Sep;14(9):1146-50. PubMed PMID: 9327440. 11: Kawamura M, Tsuji N, Moriya N, Terashita Z. Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys. Thromb Res. 1997 May 15;86(4):275-85. PubMed PMID: 9187016. 12: Kawamura M, Imura Y, Moriya N, Kita S, Fukushi H, Sugihara H, Nishikawa K, Terashita Z. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban. J Pharmacol Exp Ther. 1996 Apr;277(1):502-10. PubMed PMID: 8613960.